Gene therapy for the treatment of heart failure: promise postponed
Year: 2016
Type: review
Abstract: Gene therapy has emerged as a powerful tool in targeting the molecular mechanisms implicated in heart failure. Refinements in vector technology, including the development of recombinant adeno-associated vectors, have allowed for safe, long-term, and efficient gene transfer to the myocardium. These advancements, coupled with evolving delivery techniques, have placed gene therapy as a viable therapeutic option for patients with heart failure. However, after much promise in early-phase clinical trials, the more recent larger clinical trials have shown disappointing results, thus forcing the field to re-evaluate current vectors, delivery systems, targets, and endpoints. We provide here an updated review of current cardiac gene therapy programmes that have been or are being translated into clinical trials.
Source: European Heart Journal
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
Awards: Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors, Calcium Pump Activators for Heart Failure Therapy, TRIP: Targeted Gene Therapy for the Treatment of Heart Failure, Role of miR25 in Heart Failure, Training Program in Molecular and Cellular Cardiology, SUMO1 and SERCA2a Function, Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy, Role of STIM1 in cardiac hypertrophy and heart failure
OpenAlex ID: W2290678689
